What is Biosceptre?
Biosceptre is a pioneering biotechnology firm dedicated to the development of targeted therapeutics for cancer patients. The company is best known for its innovative BRiDGECAR system, a multiple-targeted universal CAR T platform designed to address the limitations of current oncology treatments. By combining nfP2X-targeted CAR T cells with a diverse array of antibodies, the company aims to provide a versatile solution for both liquid and solid tumors. This unique approach positions Biosceptre as a key player in the next generation of immunotherapy, with a focus on creating best-in-class treatments that could potentially improve outcomes for millions of patients worldwide.
How much funding has Biosceptre raised?
Biosceptre has raised a total of $16.4M across 4 funding rounds:
Unspecified
$4.7M
Private Equity
$671K
Series A
$10.7M
Stock/Share Issuance
$346K
Unspecified (2014): $4.7M, investors not publicly disclosed
Private Equity (2015): $671K, investors not publicly disclosed
Series A (2017): $10.7M supported by Tuspark Science and Technology Service Group
Stock/Share Issuance (2026): $346K, investors not publicly disclosed
Key Investors in Biosceptre
Tuspark Science and Technology Service Group
A large integrated enterprise established in reliance on Tsinghua University, specializing in the development and management of science parks and technology-focused investments.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Biosceptre?
With the recent capital influx, Biosceptre is well-positioned to accelerate its clinical trial programs and expand its research infrastructure. The strategic focus will likely shift toward optimizing the manufacturing processes for its CAR T systems and broadening the scope of its therapeutic applications. As the company moves into this next phase of growth, the emphasis will remain on validating the efficacy of its BRiDGECAR platform in human trials and securing the necessary regulatory approvals to bring these life-saving therapies to market. The firm's ability to maintain its momentum will be critical as it transitions from a research-heavy entity to a clinical-stage powerhouse in the global oncology market.
See full Biosceptre company page
